The effectiveness of the vaccine against coronavirus, developed by the American company Moderna, in the initial analysis was 94.1%, and in severe cases of the disease – 100%. The research results are published on the company’s website.
According to the company’s report on the first results of the third phase of the study, 30 thousand volunteers took part in the experiment. Of these, 196 people became infected with the coronavirus – these are 185 volunteers who received a placebo and 11 people who received the vaccine. This means that the drug prevents 94.1% of cases.
During Moderna’s research, one person who was part of the placebo group died of coronavirus.
This positive primary test confirms the ability of our vaccine to prevent COVID-19 disease with a 94.1% efficacy and its ability to prevent severe disease. We believe that our vaccine will be a powerful new tool that can change the course of the pandemic.
No new serious safety concerns were identified during the tests. The most common side effects are pain, redness at the injection site, fatigue, muscle or joint pain, and headache. After the second injection of the vaccine, the company said these effects were more frequent and more significant.
The company said the drug must now be approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).